Mycoplasmainhibitorsolutionisformulatedwith10mg/mlciprofloxacin.Ciprofloxacinbelongstothefluoroquinoloneantibioticfamilyandiseffectiveagainstmycoplasma,grampositiveandgramnegativebacteria[1,2].CiprofloxacininhibitsbacterialDNAgyrasenecessaryforactiveandnon-activegrowthphases[3].
Addfreshmycoplasmainhibitorsolutiontoculturemediaandchangeevery3-4days.Atwoweektreatmentshouldbesufficienttoeliminatecontamination.Theeffectiveworkingconcentrationrangesfrom5-25µg/ml;10µg/mlisidealformostapplications.Theoptimalconcentration,however,shouldbedeterminedforindividualcelltypesandcultureconditions.
Specifications:
CatalogNo. | 0563 |
CountryofManufacture | UnitedStates |
ProductCode | MIS |
Size/Quantity | 10mg/ml;10x1ml |
ProductUse | MISisforresearchuseonly.Itisnotapprovedforhumanoranimaluse,orforapplicationinclinicalorinvitrodiagnosticprocedures. |
Storage | Storeat-20°C. |
ShippingInfo | Dryice. |
References | [1]SchmittK,DaubenerW,Bitter-SuermannD,andHaddingU.(1988)"Asafeandefficientmethodforeliminationofcellculturemycoplasmasusingciprofloxacin".JImmunolMethods109:17-25.[2]DrexlerHGandUphoffCC.(2002)"Mycoplasmacontaminationofcellcultures:Incidence,sources,effects,detection,elimination,prevention".Cytotechnology39:75-90.[3]DrlicaKandZhaoX.(1997)"DNAgyrase,topoisomeraseIV,andthe4-Quinolones".MicrobiolMolBiolRev61:377-392. |